Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kalaris Therapeutics (KLRS) Gains from Investment Securities (2020)

Kalaris Therapeutics (KLRS) has 2 years of Gains from Investment Securities data on record, last reported at $3.6 million in Q3 2020.

  • For Q3 2020, Gains from Investment Securities fell 42.8% year-over-year to $3.6 million; the TTM value through Sep 2020 reached $3.6 million, changed N/A, while the annual FY2023 figure was $220000.0, 144.9% up from the prior year.
  • Gains from Investment Securities reached $3.6 million in Q3 2020 per KLRS's latest filing, up from $53683.0 in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $6.3 million in Q3 2019 and bottomed at $53683.0 in Q2 2020.